A ugusta, Georgia
Oral contraceptives are associated with serious untoward effects and have been proscribed for women over 35 years of age. It was thought that the use of a natural estrogen (pellets of 25 mg of 17ß-estradiol) implanted in descending doses (four, three, two, one) at 6-month intervals might cause less disturbance in metabolic parameters and'side effécts. Our experience with this regimen encompasses 18,480 cycles or 1,540 woman years. The corrected Pearl Index was 0.273, which compares favorably with other modes of conception control. Pellet implants proved to be quite . tool yet devised for the control of conception. However, there are many women who do not tolerate oral contraceptives, are not candidates for and do' not want an intrauterine contraceptive device, iand prefer some method other than mechanical barriers. Then, ag;ain, several authoritative bodies believe that it is prudent to limit the use of oral contraceptives to women under 35 years of age because of the rise in mortality figures for oral contraceptive llsers over that age. i Emperaire and Greenblatt2 reported that four pellets of 17ß-estradiol' (25 mg each) implanted subcutaneously at 6-month intervals provided excellent control of conception. 7 to 10 days each month in order to induce orderly periods of uterine withdrawal bleeding.
M~terial and methods
The pellets were implanted subcutaneously into the abd()men, one inch above and parallel to Pouparts ligament. A total of 490 sexually active women of reproductive age, 60% of whom were under 35 years of age, participated in this study; 410 returned for three ptllets, 351 for two pellets, and 295 stayed on for the full course. Most of the women in this latter group continued at the one-pellet level every 6 moiiths for a period ranging from 1 to 8 years. Table I shows that our experience encompassed 18,480 cycles or 1,540 woman years. The age distribution is given in Table II. Physical examinations, including blood pressure and weight, were performed every 6 months, Blood for testing with the SMA-18 was drawn at the start and at yearly intervals. Biopsy specimens of endometrium were obtained at varying intervals to study histologic changes and also whenever abnormal bleeding occurred. Hormone assays were performed in selected patien ts.
Results
Endometrial studies. Because of a belief that continuous administration of estrogen is conducive to endom~trial cancer, we obtained one or more biopsy specimens of endometrium in 148 women before and/or after a course of progestogen at varyiIlg intervals of time over a 10-year period (mean, 3.4:! 1.9 years) (Table III) . In addition, we performed 20 biopsies in i 7 women who experienced hypermènorrhea (excessive withdrawal periods) or menorrhagia (breakthrough bleeding). The mean length of time after beginning the implantation of the pellets was 3.0 :: 2.4 years ( Table IV) . Most of the patients were on a 5-day course of progestogen (either 5 mg of norethindrone or 10 mg of medroxyprogesterone acetate). Whenever we encountered any form of hyperplasia, the duration of administration of progestogen was increased to 7 to i 0 days and sometimes i 3 or. i 4 days. The frequency of hyperplasia declined rapidly and none was found by the fourth biopsy. Two hundred sixteen endometrial biopsy specimens,,obtainèd by suction curettage, were available for study (Table V) . Of the two women who had adenomatous hyperplasia, one responded to increased doses. of the progestogen with a change to a secretory endometrium; the other opted for hysterectomy.
The histopathologic characteristics of endometria of uteri from 78 women in this series of 490 was studied.
Only one case of adenomatous hyperplasia was found *Orie woman with adenomatous hyperplasia opted for hysterectomy. By increasing the length of time of progestogen administration from 5 to 10 days or longer, further occurrence of hyperplasia was prevented in those who had exhibited such. (Table VI) . In all, 294 endometria were evaluated and none revealed malignant change. Influence of pellet implants on metabolic parameters. Reports have appeared which purport to show that oral contraceptives adversely influence weight, blood pressure, glucose, and lîpid metabolism. Table   Table VI .*Two other pregnancies occurred during the first month of therapy: one patient, it appears, was pregnant prior to implantation of the pellet, and the other conceived a few days after implantation of the pellet.
cholesterol, triglycerides, and low-density lipoproteins were unchanged.
Coagulation studies were done on 11 patients at random, and no marked changes in antithrombin III were seen. In a battery of tests, levels of factor VIII were ilrrested by the administration of two tablets of the oral progestogen every 2 hours until bleeding was sta~nched(usually -0ithin 48 hours), and then two tablets per day were administered for 10 more days-a normal withdrawal period usually followed. Ten women complained öf hypermenorrhea, and when the progestogen dosage was increased from 5 or 7 days to 10 or more days, excessive withdrawal periods were corrected (Table II) . It is our. habit now to administer progestogen for 10 days in all but ã few patients.
Retention of water was not an infrequent complaint;
and in some instances a diuretic and potassium were prescribed. Tenderness and fullness in the breasts were (Table IX) . Future conception was not compromised. However, ovulation may not return for 6 to 12 months after discontinuation of pellet implants, and dnring that time the patients are advised to continue cyclic progestogen (Table X) . Six required Clomid, and two required Clomid with hCG. One patient who did not wish to become pregnant conceived 46 months after discontinuing the regimen of estradiol pellets. The ages and parity of the patients and the outcome of the pregnancies are listed in Table XI. Estradiol and estrone levels. In previous reports, we showed that estradiol and estrone were sustained at high physiologic levels on the descending-dose regirren.4.. 6 We studied the levels of estrone and estradiol in 32 women who were on the one-pellet-only regimen for 1 to 7 years. Fig. 1 
Comment
Pellet implants proved to be a worth-while alternative in those women who could not tolerate oral contraceptives, or who could not be relied upon to take their medication daily.
Ongoing investigations are in progress to learn more about the ratio of high-density to low-density lipoproteins and changes in coagulation factors with this form of medication. Of great interest also is the observation that, apparently, adequate cyclic oral progestogens are protective against the development of atypical hyperplasia of the endometrium and, thus, possibly prevent endometrial cancer in women who have been on continuous estrogen therapy for many years.
The pellet regimen was particularly welcome to the women over age 35, since many physicians refused to prescribe oral contraceptives for them. 6 The favorable results noticed make us wonder whether the systemic absorption of estrogen, rather than through the gastrointestinal tract, and immediate clearance through the liver may be the explanation for decreased interference with clotting mechanisms, triglycerides, cholesterol metabolism, and glucose. Further studies are indicated to learn whether the use of a natural estrogen (£2) induces less metabolic derangement than do the synthetic estrogens (ethinyl estradiol and mestranol).
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